Taub Rebecca Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$50.79M

Insider Activity of Taub Rebecca

According to the SEC Form 4 filings, Taub Rebecca, being in a position of

  1. director at Madrigal Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 40676 shares for $21.68M,
    over all time since 2018-06-11, has bought 0 shares, and sold 312073 shares for $99.6M.

Biography of Taub Rebecca

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $21,675,9875100

Comparison of Insiders on Amount of Buys and Sells

2026-03-06SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
491
0.0022%
$431.94$212,083+18.78%
2026-01-26SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
647
0.0028%
$492.42$318,596+2.53%
2026-01-20SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
2,238
0.0096%
$490.77$1.1M+1.07%
2026-01-09SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
18,650
0.0855%
$522.76$9.75M-0.78%
2025-12-10SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
18,650
0.0838%
$552.15$10.3M-7.21%
2025-08-12SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
43,263
0.1975%
$355.69$15.39M+39.24%
2025-08-11SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
3,200
0.0144%
$350.24$1.12M+42.99%
2025-07-18SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
1,000
0.0047%
$350.00$350,005+46.51%
2025-07-17SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
2,657
0.0122%
$350.41$931,035+40.31%
2025-07-16SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
26,444
0.122%
$353.47$9.35M+41.83%
2025-01-24SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
648
0.003%
$335.24$217,236+4.67%
2025-01-17SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
1,689
0.0072%
$273.41$461,789+16.28%
2024-04-08SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
2,676
0.0126%
$245.99$658,258+12.26%
2024-04-05SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
27,506
0.1312%
$243.36$6.69M+14.57%
2024-04-05SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
22,228
0.1058%
$242.84$5.4M+14.57%
2024-04-04SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
18,537
0.0888%
$242.91$4.5M+15.31%
2024-04-04SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
13,339
0.0636%
$241.81$3.23M+15.31%
2024-04-03SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
27,845
0.1399%
$245.14$6.83M+13.2%
2024-04-03SaleMadrigal Pharmaceuticals, Inc.
MDGL
Pres., R&D, and CMO
6,839
0.0342%
$244.24$1.67M+13.2%
2018-06-11SaleMadrigal Pharmaceuticals, Inc.
MDGL
Chief Medical Officer, EVP R&D
73,526
0.5365%
$287.46$21.14M-50.82%
Total: 20
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.